Unmet Needs in the Treatment of Schizophrenia: New Targets to Help Different Symptom Domains
Unmet Needs in the Treatment of Schizophrenia: New Targets to Help Different Symptom Domains
复制标题
DOI：
10.4088/jcp.13049su1c.04
复制
发表时间：
2014-01-01
影响因子：
5.3
通讯作者：
Citrome, Leslie
中科院分区：
文献类型：
--
作者：
Citrome, Leslie
目前的精神分裂症治疗方法虽然对阳性症状有效，但尚未证明对阴性症状和认知功能障碍有效。其他策略，如联合抗精神病药物或在抗精神病药物中添加辅助药物，在阴性和认知症状领域也产生了令人失望的结果。然而，n -甲基-d-天冬氨酸（NMDA）受体功能低下假说，其重点是谷氨酸系统对多巴胺的影响，可以解释精神分裂症的阳性、阴性和认知症状。目前正在探索的治疗靶点主要集中在NMDA受体（如甘氨酸、d-丝氨酸）、甘氨酸再摄取抑制（如肌氨酸和bitopertin），以及通过不同途径的a-7烟碱乙酰胆碱受体激动作用（如encenicline）。
Current treatments for schizophrenia, although effective for positive symptoms, have not proven as effective for negative symptoms and cognitive dysfunction. Additional strategies, such as combining antipsychotics or adding adjunctive agents to antipsychotics, have also yielded disappointing results in both negative and cognitive symptom domains. However, the N-methyl-d-aspartate (NMDA) receptor hypofunction hypothesis, with its focus on the glutamate system's effect on dopamine, can explain the positive, negative, and cognitive symptoms in schizophrenia. Therapeutic targets are being explored that focus on NMDA receptors (eg, glycine, d-serine), glycine reuptake inhibition (such as sarcosine and bitopertin), and, through a different pathway, a-7 nicotinic acetylcholine receptor agonism (eg, encenicline).